Liggins Institute, University of Auckland, Auckland, New Zealand; Newborn Services, Auckland City Hospital, Auckland, New Zealand.
Newborn Services, Auckland City Hospital, Auckland, New Zealand; Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand.
J Pediatr. 2021 Aug;235:107-115.e4. doi: 10.1016/j.jpeds.2021.03.057. Epub 2021 Mar 30.
To determine the effects of different doses of prophylactic dextrose gel on glycemic stability assessed using continuous glucose monitoring in the first 48 hours when given to babies at risk of neonatal hypoglycemia.
Continuous glucose monitoring was undertaken for the first 48 hours in 133 infants at risk of hypoglycemia who participated in the pre-hPOD randomized dosage trial of dextrose gel prophylaxis.
Low glucose concentrations were detected in 41% of infants by blood glucose monitoring and 68% by continuous interstitial glucose monitoring. The mean ± SD duration of low interstitial glucose concentrations was 295 ± 351 minutes in the first 48 hours. Infants who received any dose of dextrose gel seemed to be less likely than those who received placebo gel to experience low glucose concentrations (<47 mg/dL [2.6 mmol/L]; P = .08), particularly if they received a single dose of 200 mg/kg (relative risk, 0.70; 95% CI, 0.50-0.10; P = .049). They also spent a greater proportion of time in the central glucose concentration range of 54-72 mg/dL (3-4 mmol/L) (any dose, mean ± SD, 58.2 ± 20.3%; placebo, 50.0 ± 21.9%; mean difference, 8.20%; 95% CI, 0.43-15.9%; P = .038). Dextrose gel did not increase recurrent or severe episodes of low glucose concentrations and did not increase the peak glucose concentration. These effects were similar for all trial dosages.
Low glucose concentrations were common in infants at risk of hypoglycemia despite blood glucose monitoring and treatment. Prophylactic dextrose gel reduced the risk of hypoglycemia without adverse effects on glucose stability.
评估预防性葡聚糖凝胶在新生儿低血糖风险婴儿出生后 48 小时内使用连续血糖监测时对血糖稳定性的影响。
133 名低血糖风险婴儿参与了葡聚糖凝胶预防剂量的预 hPOD 随机剂量试验,对他们进行了 48 小时的连续血糖监测。
通过血糖监测发现 41%的婴儿存在低血糖,通过连续间质葡萄糖监测发现 68%的婴儿存在低血糖。在最初的 48 小时内,间质葡萄糖浓度低的平均持续时间为 295 ± 351 分钟。与接受安慰剂凝胶的婴儿相比,接受任何剂量葡聚糖凝胶的婴儿似乎不太可能出现低血糖浓度(<47mg/dL [2.6mmol/L];P =.08),特别是如果他们接受单次 200mg/kg 的剂量(相对风险,0.70;95%CI,0.50-0.10;P =.049)。他们也有更大的比例处于 54-72mg/dL(3-4mmol/L)的中心葡萄糖浓度范围(任何剂量,平均 ± 标准差,58.2 ± 20.3%;安慰剂,50.0 ± 21.9%;平均差异,8.20%;95%CI,0.43-15.9%;P =.038)。葡聚糖凝胶不会增加低血糖的反复发作或严重发作,也不会增加血糖峰值。这些效果在所有试验剂量中都相似。
尽管进行了血糖监测和治疗,低血糖风险婴儿仍经常出现低血糖。预防性葡聚糖凝胶降低了低血糖的风险,而不会对血糖稳定性产生不利影响。